Compositions and methods for increasing protein expression

HK40137437APending Publication Date: 2026-09-11THE HONG KONG UNIV OF SCI & TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026125676
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-13
Filing Date
2026-07-03
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Compositions and methods comprising an artificial poly (A) sequence having at least one cytosine and at least one uridine and / or guanosine are provided.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480041650.2 (22) Application Date 2024.07.12 (30) Priority Data 63 / 513,354 2023.07.13 US (85) PCT International Application Entering National Phase Date 2025.12.22 (86) PCT International Application Application Data PCT / CN2024 / 105157 2024.07.12 (87) PCT International Application Publication Data WO2025 / 011636 EN 2025.01.16 (71) Applicant: Hong Kong University of Science and Technology Address: Clear Water Bay, Kowloon, Hong Kong, China (72) Inventors: Kuang Yi, Li Zhuoran, Qiu Weilan, Cheng Chen (74) Patent Agency: Beijing Ying Sai Jia Hua Intellectual Property Agency Co., Ltd. 11204 Patent Attorney Hong Xinyi Shuo (51) Int.Cl. C12N 15 / 67 (2006.01) (54) Title of Invention Composition and Method for Improving Protein Expression (57) Abstract Compositions and methods comprising an artificial poly(A) sequence having at least one cytosine and at least one uridine and / or guanosine. Claims 3 pages Description 16 pages Drawings 4 pages CN 121368634 A 2026.01.20 CN 1 21 36 86 34 A 1. An artificial poly(A) sequence comprising about 30-150 adenines, wherein in the last third portion of the artificial poly(A) sequence closest to its 3' end, at least one adenine is substituted with cytosine and at least one adenine is substituted with uridine or guanosine. 2. The artificial poly(A) sequence of claim 1, wherein in the last third portion of the artificial poly(A) sequence closest to its 3' end, at least one adenine is substituted with cytosine, at least one adenine is substituted with uridine, and at least one adenine is substituted with guanosine. 3. The artificial poly(A) sequence of claim 1 or 2, wherein the artificial poly(A) sequence comprises 18 to 129 adenines. 4. The artificial poly(A) sequence of any one of claims 1 to 3, wherein the last nucleotide in the artificial poly(A) sequence is not cytosine. 5. The artificial poly(A) sequence of any one of claims 1 to 4, wherein up to 40% of the nucleotides in the artificial poly(A) sequence are cytosine. 6. The artificial poly(A) sequence of claim 5, wherein up to 25% of the nucleotides in the artificial poly(A) sequence are cytosine.7. The artificial poly(A) sequence of any one of claims 1 to 6, wherein most of the cytosines in the artificial poly(A) sequence are located in the last third portion of the artificial poly(A) sequence closest to its 3' end. 8. The artificial poly(A) sequence of any one of claims 1 to 7, wherein all cytosines in the artificial poly(A) sequence are sequentially located. 9. The artificial poly(A) sequence of any one of claims 1 to 8, wherein the artificial poly(A) sequence comprises about 40 adenines, and between nucleotides 27 and 39 of the artificial poly(A) sequence, at least one adenine is substituted with cytosine and at least one adenine is substituted with uridine or guanosine. 10. The artificial poly(A) sequence of any one of claims 1 to 9, wherein the artificial poly(A) sequence comprises about 40 adenines, and between nucleotides 27 and 39 of the artificial poly(A) sequence, at least one adenine is substituted with cytosine, at least one adenine is substituted with uridine, and at least one adenine is substituted with guanosine. 11. The artificial poly(A) sequence of claim 9 or 10, wherein the artificial poly(A) sequence comprises 24 to 39 adenines. 12. The artificial poly(A) sequence of any one of claims 9 to 11, wherein the artificial poly(A) sequence comprises 1 to 16 cytosines. 13. The artificial poly(A) sequence of any one of claims 9 to 12, wherein all cytosines in the artificial poly(A) sequence are located between the 25th and 39th nucleotides of the artificial poly(A) sequence. 14. The artificial poly(A) sequence of any one of claims 9 to 13, wherein all cytosines in the artificial poly(A) sequence are sequentially located. 15. The artificial poly(A) sequence of any one of claims 9 to 14, wherein the last nucleotide in the artificial poly(A) sequence is not a cytosine. 16. The artificial poly(A) sequence of any one of claims 1 to 8, wherein the artificial poly(A) sequence comprises about 60 adenines, and between the 41st and 59th nucleotides of the artificial poly(A) sequence, at least one adenine is substituted with cytosine and at least one adenine is substituted with uridine or guanosine. 17. The artificial poly(A) sequence of claim 16, wherein the artificial poly(A) sequence comprises 36 to 59 adenines. Claims 1 / 3 page 2 CN 121368634 A 18. The artificial poly(A) sequence of claim 16 or 17, wherein the artificial poly(A) sequence comprises 1 to 24 cytosines.19. The artificial poly(A) sequence of any one of claims 16 to 18, wherein all cytosines in the artificial poly(A) sequence are located between nucleotides 37 and 59 of the artificial poly(A) sequence. 20. The artificial poly(A) sequence of any one of claims 16 to 19, wherein all cytosines in the artificial poly(A) sequence are sequentially located. 21. The artificial poly(A) sequence of any one of claims 16 to 20, wherein the last nucleotide in the artificial poly(A) sequence is not a cytosine. 22. The artificial poly(A) sequence of any one of claims 1 to 8, wherein the artificial poly(A) sequence comprises about 100 adenines, and between nucleotides 67 and 99 of the artificial poly(A) sequence, at least one adenine is substituted with a cytosine and at least one adenine is substituted with uridine or guanosine. 23. The artificial poly(A) sequence of claim 22, wherein the artificial poly(A) sequence comprises 60 to 99 adenines. 24. The artificial poly(A) sequence of claim 22 or 23, wherein the artificial poly(A) sequence comprises 1 to 40 cytosines. 25. The artificial poly(A) sequence of any one of claims 22 to 24, wherein all cytosines in the artificial poly(A) sequence are located between nucleotides 61 and 99 of the artificial poly(A) sequence. 26. The artificial poly(A) sequence of any one of claims 22 to 25, wherein all cytosines in the artificial poly(A) sequence are sequentially located. 27. The artificial poly(A) sequence of any one of claims 22 to 26, wherein the last nucleotide in the artificial poly(A) sequence is not a cytosine. 28. The artificial poly(A) sequence of any one of claims 1 to 27, wherein the artificial poly(A) sequence comprises a sequence of any one of SEQ ID NO: 2-8 and 10. 29. An expression cassette comprising a promoter and a polynucleotide sequence encoding the artificial poly(A) sequence of any one of claims 1 to 27. 30. The expression cassette of claim 29, further comprising a multiple cloning site between the promoter and the polynucleotide sequence encoding the artificial poly(A) sequence. 31. The expression cassette of claim 29 or 30, further comprising a transcription start codon and a transcription stop codon, both operatively linked to the promoter and the polynucleotide sequence encoding the artificial poly(A) sequence.32. The expression cassette of any one of claims 29 to 31, further comprising a polynucleotide sequence encoding a polypeptide between the promoter and the artificial poly(A) sequence, wherein the polynucleotide sequence is operatively linked to the promoter and the polynucleotide sequence encoding the artificial poly(A) sequence. 33. An expression vector comprising the expression cassette of any one of claims 29 to 32. 34. A host cell comprising the expression cassette of any one of claims 29 to 32 or the expression vector of claim 33. 35. An RNA polynucleotide expressed by the expression cassette of claim 32. 36. An RNA molecule comprising a coding sequence for a polypeptide and an artificial poly(A) sequence of any one of claims 1 to 27. 37. A method for enhancing intracellular protein expression of a polypeptide, comprising transfecting the cell of claim 33 with the expression vector of claim 33. Claims 3 / 3 Page 4 CN 121368634 A Composition and method for improving protein expression

[0001] Related Applications

[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 513,354, filed July 13, 2023, the contents of which are incorporated herein by reference in their entirety for all purposes.

[0003] Background

[0004] Messenger RNA (mRNA) is a key molecule in the flow of genetic information. mRNA is a long chain of nucleotides that encodes protein information from the genome. They produce all the proteins in the cell and are therefore one of the essential biomolecules for life. Although mRNA has been the subject of basic biological research for half a century, it has only been recognized and developed as a potentially new and powerful therapeutic tool in the last two decades. Synthetic mRNA therapeutics, also known as mRNA drugs, have several advantages over their DNA- and protein-based counterparts. mRNA does not carry the risk of genome integration because it is readily processed in the cytoplasm and does not enter the nucleus. It is also completely degraded by endogenous physiological metabolic pathways, allowing for a transient effect beneficial to drugs. Furthermore, mRNA naturally possesses sensory units, allowing it to regulate protein production based on the presence of biomolecules in the cell. In 1990, Wolff et al. demonstrated that injecting engineered mRNA into mice could express the encoded protein in vivo. This discovery led many research groups in the 1990s to explore various applications of mRNA for biomedical purposes, such as gene therapy and vaccination. Despite promising results, mRNA therapeutics face challenges regarding their instability and high immunogenicity. Because mRNA degrades naturally in biological systems, high doses or repeated administration are often required.There exist artificial sequences and chemically modified nucleotides that, when placed in UTR and / or ORF sequences, can enhance the performance of mRNA. There is a need for compositions and methods capable of improving mRNA stability.

[0005] Brief Overview

[0006] In one aspect, the present disclosure is characterized by an artificial poly(A) sequence comprising about 30-150 consecutive (e.g., about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150) strings of adenine, wherein in the last third portion of the artificial poly(A) sequence closest to its 3' end, at least one adenine is substituted with cytosine and at least one adenine is substituted with uridine or guanosine. In some embodiments, in the last third of the artificial poly(A) sequence closest to its 3' end, at least one adenine is substituted with cytosine, at least one adenine is substituted with uridine, and at least one adenine is substituted with guanosine. In some embodiments, the artificial poly(A) sequence comprises 18 to 149 (e.g., 18 to 120, 18 to 110, 18 to 100, 18 to 90, 18 to 80, 18 to 70, 18 to 60, 18 to 50, 18 to 40, 18 to 30, 18 to 20, 30 to 129, 40 to 129, 50 to 129, 60 to 129, 70 to 129, 80 to 129, 90 to 129, 100 to 129, 110 to 129, 120 to 129, 130 to 139, 140 to 149) consecutive adenines, wherein at least one, and possibly more, are substituted with cytosine, uridine, and / or guanosine. In some embodiments, the last nucleotide in the artificial poly(A) sequence is not cytosine.

[0007] In some embodiments, up to 40% (e.g., 2%, 4%, 6%, 8%, 10%, 12%, 14%, 16%, 18%, 20%, 22%, 24%, 26%, 28%, 30%, 32%, 34%, 36%, 38%, or 40%) of the nucleotides in the artificial poly(A) sequence are cytosine. In some embodiments, up to 25% (e.g., 2%, 4%, 6%, 8%, 10%, 12%, 14%, 16%, 18%, 20%, 22%, or 24%) of the nucleotides in the artificial poly(A) sequence are cytosine.

[0008] In some embodiments, the majority of the cytosines in the artificial poly(A) sequence (i.e., 90% or more of the cytosines) are located in the last third of the artificial poly(A) sequence, closest to its 3' end.Furthermore, in some embodiments, all cytosines in the artificial poly(A) sequence are sequentially positioned.

[0009] In a particular embodiment, the artificial poly(A) sequence comprises about 40 adenines, and between nucleotides 27 and 39 of the artificial poly(A) sequence, at least one adenine is substituted with cytosine and at least one adenine is substituted with uridine or guanosine. In some embodiments, between nucleotides 27 and 39 of the artificial poly(A) sequence, at least one adenine is substituted with cytosine, at least one adenine is substituted with uridine, and at least one adenine is substituted with guanosine. In some embodiments, the artificial poly(A) sequence comprises 24 to 39 (e.g., 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39) adenines. In some embodiments, the artificial poly(A) sequence contains 1 to 16 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16) cytosines. In some embodiments, all cytosines in the artificial poly(A) sequence are located between nucleotides 25 and 39 of the artificial poly(A) sequence. Furthermore, in some embodiments, all cytosines in the artificial poly(A) sequence are sequentially located. In some embodiments, the last nucleotide in the artificial poly(A) sequence is not a cytosine.

[0010] In a particular embodiment, the artificial poly(A) sequence contains about 60 adenines, and between nucleotides 41 and 59 of the artificial poly(A) sequence, at least one adenine is substituted with a cytosine and at least one adenine is substituted with uridine or guanosine. In some embodiments, between nucleotides 41 and 59 of the artificial poly(A) sequence, at least one adenine is substituted with cytosine, at least one adenine is substituted with uridine, and at least one adenine is substituted with guanosine. In some embodiments, the artificial poly(A) sequence contains 36 to 59 (e.g., 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, or 59) adenines. In some embodiments, the artificial poly(A) sequence contains 1 to 24 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24) cytosines.In some embodiments, all cytosines in the artificial poly(A) sequence are located between nucleotides 37 and 59 of the artificial poly(A) sequence. Furthermore, in some embodiments, all cytosines in the artificial poly(A) sequence are sequentially located. In some embodiments, the last nucleotide in the artificial poly(A) sequence is not a cytosine.

[0011] In a particular embodiment, the artificial poly(A) sequence contains about 100 adenines, and between nucleotides 67 and 99 of the artificial poly(A) sequence, at least one adenine is substituted with a cytosine and at least one adenine is substituted with uridine or guanosine. In some embodiments, between nucleotides 67 and 99 of the artificial poly(A) sequence, at least one adenine is substituted with a cytosine, at least one adenine is substituted with uridine, and at least one adenine is substituted with guanosine. In some implementations, the artificial poly(A) sequence contains 60 to 99 (e.g., 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99) adenines. In some embodiments, the artificial poly(A) sequence comprises 1 to 40 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40) cytosines. In some embodiments, all cytosines in the artificial poly(A) sequence are located between nucleotides 61 and 99 of the artificial poly(A) sequence. Furthermore, in some embodiments, all cytosines in the artificial poly(A) sequence are sequentially located. In some embodiments, the last nucleotide in the artificial poly(A) sequence is not a cytosine. When present at the 3' end of a sequence encoding a polypeptide in an mRNA molecule, the claimed poly(A) of this invention improves the stability of the mRNA. Further improvements in stability are achieved synergistically through additional modifications to the mRNA (including 5' cap modifications, artificial 5' and 3' UTR sequences, and coding regions with optimized codons) and chemical modifications to the mRNA, such as replacing naturally occurring nucleotides with non-naturally occurring nucleotides (e.g., pseudouridine and 5-methylcytosine).

[0012] In some embodiments, the artificial poly(A) sequence comprises the sequence of any one of SEQ ID NO: 2-8 and 10.Specification 2 / 16 Page 6 CN 121368634 A

[0013]

[0014] This disclosure is further characterized by an expression cassette comprising a promoter and a nucleotide sequence encoding the artificial poly(A) sequence described herein. In some embodiments, the expression cassette further comprises a multiple cloning site between the promoter and the coding sequence of the artificial poly(A) sequence to allow insertion of a polynucleotide sequence encoding a target protein that is operatively linked to the promoter and the sequence encoding the poly(A) sequence. In some embodiments, the expression cassette further comprises a transcription start codon and a transcription stop codon, both operatively linked to the promoter and the sequence encoding the artificial poly(A) sequence. In a particular embodiment, the expression cassette further comprises a polynucleotide sequence encoding a polypeptide (e.g., the polypeptide may be a therapeutic protein or an antigen (e.g., an antigen from a viral pathogen, bacterial pathogen, or fungal pathogen)) between the promoter and the sequence encoding the artificial poly(A) sequence, wherein the polynucleotide sequence is operatively linked to the promoter and the sequence encoding the artificial poly(A) sequence. In some embodiments, the polypeptide may be a natural antigen or a portion thereof derived from a cell, such as OVA MHC class I epitope SIINFEKL (SEQ ID NO:11) or a portion thereof.

[0015] This disclosure also provides expression vectors (e.g., circularized vectors such as plasmids or viral vectors) comprising the expression cassette described herein.

[0016] In another aspect, this disclosure also provides host cells comprising the expression cassette or expression vector described herein.

[0017] In another aspect, this disclosure provides RNA polynucleotides expressed by the expression cassette described herein, and RNA molecules containing a polynucleotide sequence encoding a polypeptide (e.g., a therapeutic protein or antigen (e.g., an antigen from a viral pathogen, bacterial pathogen, or fungal pathogen)) from the 5' end to the 3' end, and a poly(A) sequence as described above and herein. In some embodiments, the polypeptide may be a natural antigen or a portion thereof derived from a cell, such as OVA MHC class I epitope SIINFEKL (SEQ ID NO:11) or a portion thereof.

[0018] In other aspects, this disclosure provides methods for enhancing the expression of intracellular peptides (e.g., the peptide may be a therapeutic protein or an antigen (e.g., an antigen from a viral pathogen, bacterial pathogen, or fungal pathogen)), (Page 3 / 16, CN 121368634 A) which includes transfecting said cells with the expression vector described herein. In some embodiments, the peptide may be a natural antigen derived from the cell or a portion thereof, such as the OVA MHC class I epitope SIINFEKL (SEQ ID NO:11) or a portion thereof.

[0019] Brief Description of the Figures

[0020] Figure 1 shows the relative EGFP expression in HEK293 cells 24 hours after transfection with EGFP mRNAs with different tail sequences. n=3; data are expressed as mean ± SD.

[0021] Figure 2 shows the relative EGFP expression in HEK293 cells 24 hours after transfection with EGFP mRNAs with different tail sequences and cap analogs. n=3; data are expressed as mean ± SD.

[0022] Figure 3 shows the relative EGFP expression in MCF-7 cells 24 hours after transfection with EGFP mRNAs with different tail sequences and cap analogs. n=3; data are expressed as mean ± SD.

[0023] Figure 4 shows the relative EGFP expression in HEK293 cells 24 hours after transfection with EGFP mRNAs with different tail sequences and cap analogs. n=3; data are expressed as mean ± SD.

[0024] Detailed Description

[0025] I. Introduction

[0026] The inventors of this application have discovered that artificial poly(A) sequences containing adenine and at least one cytosine can effectively enhance protein expression from RNA sequences when linked to the 3' end of an RNA sequence (see, for example, Li et al., Mol Ther Nucleic Acids, 2022, 30:300-310, incorporated herein by reference in its entirety). These artificial poly(A) sequences can be used for simple and smart model mRNA drugs with cell type-independent and reagent-independent effects. Since artificial poly(A) sequences can be easily incorporated into DNA templates via conventional PCR reactions, no additional cost is required to synthesize mRNA drugs carrying artificial poly(A) sequences. Artificial poly(A) sequences can be used in conjunction with other mRNA technologies, including modified nucleotides and modified cap analogs. Therefore, these artificial poly(A) sequences can be widely used in existing and future mRNA drugs to enhance efficacy and reduce costs.

[0027] II. Definitions

[0028] As used herein, the term "artificial poly(A) sequence" refers to an RNA polynucleotide containing a continuous string of adenines, wherein at least one adenine is replaced by cytosine. Typically, the last nucleotide in an artificial poly(A) sequence is not cytosine.

[0029] As used herein, the phrase "the last third of an artificial poly(A) sequence closest to its 3' end" refers to the nucleotides located near the 3' end of the artificial poly(A) sequence, wherein these nucleotides constitute one-third of all nucleotides in the sequence. For example, if an artificial poly(A) sequence has 40 nucleotides, then the last third of an artificial poly(A) sequence closest to its 3' end refers to nucleotides 27 through 40.In another instance, if an artificial poly(A) sequence has 20 nucleotides, the last third of the artificial poly(A) sequence closest to its 3' end refers to nucleotides 14 through 20.

[0030] As used herein, the term "about" indicates a range of values ​​+ / - 10% of a specified value. For example, "about 40" indicates a range of values ​​40 + / - 40 × 10%, i.e., 36 to 44.

[0031] As used herein, the term "between" indicates a range of values ​​set within a lower and upper limit, including both the lower and upper limits. For example, nucleotides between the 27th and 39th nucleotides of a polynucleotide containing a total of 40 nucleotides can be the 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, or 39th nucleotide.

[0032] The term “expression cassette” refers to a recombinant or synthetically produced nucleic acid construct having a specific set of nucleic acid elements that allow transcription of a specific polynucleotide sequence in a host cell. An expression cassette may be part of a circular construct, such as a plasmid, viral genome, or vector, or a longer nucleic acid fragment. Typically, an expression cassette comprises a polynucleotide to be transcribed that is operatively linked to a promoter (e.g., a heterologous promoter). In this context, “operatively linked” means placing two or more genetic elements, such as a polynucleotide coding sequence and a promoter, in relative positions that allow the elements (e.g., promoters that direct transcription of coding sequences) to perform their appropriate biological functions. Other elements (e.g., heterologous elements) that may be present in an expression cassette include those that enhance transcription (e.g., enhancers) and terminate transcription (e.g., terminators), as well as those that confer certain binding affinity or antigenicity to recombinant proteins produced by the expression cassette.

[0033] The term “multiple cloning site” refers to a short nucleotide sequence containing multiple restriction endonuclease recognition sites that allow insertion into another sequence encoding RNA or protein.

[0034] The term “nucleic acid” refers to deoxyribonucleotides or ribonucleotides in single-stranded or double-stranded form, polymers thereof, and their complements. The term covers nucleic acids containing known nucleotide analogs or modified backbone residues or bonds that are synthetic, naturally occurring, or non-natural, have similar binding properties to a reference nucleic acid, and are metabolized in a similar manner to a reference nucleotide. Examples of such analogs include, but are not limited to, thiophosphates, aminophosphates, methylphosphonates, chiral methylphosphonates, 2-O-methylribonucleotides, and peptide nucleic acids (PNAs).

[0035] Unless otherwise stated, specific nucleic acid sequences also implicitly cover variants of their conserved modifications (e.g., degenerate codon substitutions) and complementary sequences, as well as explicitly stated sequences.Specifically, degenerate codon substitution can be achieved by producing a sequence in which the third position of one or more selected (or all) codons is substituted with a mixture of bases and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).

[0036] As used herein, the term “polynucleotide” refers to oligonucleotides or nucleotides and fragments or portions thereof, as well as DNA or RNA of genomic or synthetic origin, which may be single-stranded or double-stranded and represents a sense strand or antisense strand. A single polynucleotide is translated into a single polypeptide.

[0037] As used herein, the terms “peptide” and “polypeptide” are used interchangeably and describe a single polymer in which monomers are linked together by amide bonds of amino acid residues. The term "peptide" is intended to encompass any amino acid sequence that is naturally occurring, recombinant, or synthetically produced.

[0038] In the context of two or more nucleic acid or peptide sequences, the term "identical" or "percentage of identity" means that two or more sequences or subsequences are identical or have the same specified percentage of amino acid residues or nucleotides (i.e., approximately 60% identical in a specified region when performing comparisons and alignments with maximum correspondence on a comparison window or specified region, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more), as measured below using the BLAST 2.0 sequence comparison algorithm with default parameters, or by manual alignment and visual inspection (see, for example, the NCBI website ncbi.nlm.nih.gov / BLAST / etc.). Such sequences are then considered "substantially identical." As described below, preferred algorithms may take into account vacancies, etc. Preferably, the identity exists in a region of at least about 25 amino acids or nucleotides in length, or more preferably in a region of 50-100 or more amino acids or nucleotides in length.

[0039] For sequence comparison, typically one sequence is used as a reference sequence, and the test sequence is compared with that reference sequence. When using a sequence comparison algorithm, the test sequence and the reference sequence are input into a computer, and subsequence coordinates are specified if necessary, and sequence algorithm program parameters are specified. Preferably, default program parameters can be used, or alternative parameters can be specified. The sequence comparison algorithm then calculates the percentage of sequence identity of the test sequence relative to the reference sequence based on the program parameters.

[0040] As used herein, a “comparison window” includes a segment of any one of a plurality of consecutive positions selected from 20 to 600, typically about 50 to about 200, more typically about 100 to about 150, as described on page 5 / 16 of the specification, CN 121368634 A, wherein, after optimal alignment of two sequences, one sequence can be compared with a reference sequence of the same number of consecutive positions. Methods for aligning sequences used for comparison are well known in the art.

[0041] Algorithms suitable for determining the percentage of sequence identity and the percentage of sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990), respectively. BLAST and BLAST 2.0, together with the parameters described herein, are used to determine the percentage of sequence identity of nucleic acids and proteins of this disclosure. The software used for BLAST analysis is publicly available from the National Center for Biotechnology Information (http: / / www.ncbi.nlm.nih.gov / ). The algorithm involves first identifying high-scoring sequence pairs (HSPs) by identifying short characters of length W in the query sequence that match or satisfy a positive threshold score T when compared to characters of the same length in a database sequence. T is referred to as the neighboring character score threshold (Altschul et al., ibid.). These initial neighboring character hits serve as seeds for initiating searches for longer HSPs containing them. Character hits are extended in both directions along each sequence until the cumulative alignment score increases. For nucleotide sequences, the cumulative score is calculated using parameters M (reward score for matching residue pairs; always >0) and N (penalty score for mismatched residues; always <0). For amino acid sequences, a scoring matrix is ​​used to calculate the cumulative score. The extension of a character hit in each direction is terminated when: the cumulative alignment score drops by X from its maximum realized value; the cumulative score reaches 0 or below 0 due to the accumulation of one or more negative residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the alignment sensitivity and speed. The BLASTN program (for nucleotide sequences) defaults to: word length (W) 11, expected value (E) 10, M=5, N=-4, and two-strand comparison.For amino acid sequences, the BLASTP program defaults to: word length 3, expected value (E) 10, and BLOSUM62 score matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignment (B) 50, expected value (E) 10, M=5, N=-4, and comparison of two strands.

[0042] III. Artificial poly(A) sequence

[0043] This disclosure provides an artificial poly(A) sequence having at least one cytosine. The artificial poly(A) sequence may contain about 30-130 adenines, wherein in the last third portion of the artificial poly(A) sequence closest to its 3' end, at least one adenine is substituted with cytosine and at least one adenine is substituted with uridine or guanosine. In some embodiments, the artificial poly(A) sequence may contain 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 adenines, wherein in the last third of the artificial poly(A) sequence closest to its 3' end, at least one adenine is substituted with cytosine and at least one adenine is substituted with uridine or guanosine. For example, in the last third of the artificial poly(A) sequence closest to its 3' end, at least one adenine is substituted with cytosine, at least one adenine is substituted with uridine, and at least one adenine is substituted with guanosine. In other embodiments, two or more adenines in the artificial poly(A) sequence are substituted with cytosine, and at least one cytosine is located in the last third of the artificial poly(A) sequence closest to its 3' end. In other embodiments, two, three, four, or more adenine nucleotides in the artificial poly(A) sequence are replaced by uridine. In other embodiments, two, three, four, or more adenine nucleotides in the artificial poly(A) sequence are replaced by guanosine.

[0044] In some embodiments of the artificial poly(A) sequence, up to 40% (e.g., 2%, 4%, 6%, 8%, 10%, 12%, 14%, 16%, 18%, 20%, 22%, 24%, 26%, 28%, 30%, 32%, 34%, 36%, 38%, or 40%) of the nucleotides in the artificial poly(A) sequence are cytosine. In some embodiments of the artificial poly(A) sequence, 60% to 98% (e.g., 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, or 98%) of the nucleotides in the artificial poly(A) sequence are adenine.In some implementations, the artificial poly(A) sequence may contain 18 to 129 (e.g., 18 to 120, 18 to 110, 18 to 100, 18 to 90, 18 to 80, 18 to 70, 18 to 60, 18 to 50, 18 to 40, 18 to 30, 18 to 20, 30 to 129, 40 to 129, 50 to 129, 60 to 129, 70 to 129, 80 to 129, 90 to 129, 100 to 129, 110 to 129, 120 to 129) adenines. In some embodiments, the artificial poly(A) sequence may contain 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) cytosines. In some embodiments of the artificial poly(A) sequence described herein, the last nucleotide in the artificial poly(A) sequence is not a cytosine.

[0045] In some embodiments of the artificial poly(A) sequence described herein, the majority of the cytosines in the artificial poly(A) sequence (i.e., 90% or more of the cytosines) are located in the last third portion of the artificial poly(A) sequence closest to its 3' end. The cytosines in the artificial poly(A) sequence may be continuously positioned, i.e., located in a continuous chain of cytosines without any adenine in between. In some embodiments, the cytosines in the artificial poly(A) sequence may be continuously located in the last third portion of the artificial poly(A) sequence closest to its 3' end, wherein the last nucleotide in the artificial poly(A) sequence is not a cytosine. In other embodiments, cytosine in the artificial poly(A) sequence may be distributed throughout (i.e., adenine may be located between cytosines) the entire length of the artificial poly(A) sequence. In some embodiments, cytosine in the artificial poly(A) sequence may be distributed throughout the last third of the artificial poly(A) sequence closest to its 3' end, wherein the last nucleotide in the artificial poly(A) sequence is not cytosine.

[0046] In particular, the artificial poly(A) sequence may contain about 40 adenines, and between the 27th and 39th nucleotides of the artificial poly(A) sequence, at least one adenine is substituted with cytosine and at least one adenine is substituted with uridine or guanosine (e.g., at least one adenine is substituted with cytosine, at least one adenine is substituted with uridine, and at least one adenine is substituted with guanosine), wherein the last nucleotide in the artificial poly(A) sequence is not cytosine.In some embodiments of such an artificial poly(A) sequence, the sequence may contain 1 to 16 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16) cytosines. In some embodiments of such an artificial poly(A) sequence, the sequence may contain 24 to 39 (e.g., 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39) adenines. In some embodiments of this artificial poly(A) sequence, all cytosines in the artificial poly(A) sequence are located between nucleotides 25 and 39 of the artificial poly(A) sequence (e.g., between nucleotides 26 and 39, 27 and 39, 28 and 39, 29 and 39, 30 and 39, 31 and 39, 32 and 39, 33 and 39, 34 and 39, 35 and 39, 36 and 39, or 37 and 39). In some embodiments, all cytosines in the artificial poly(A) sequence are sequentially located, i.e., located in a continuous chain of cytosines without any adenine in between. In some embodiments, all cytosines in the artificial poly(A) sequence are sequentially located between nucleotides 25 to 39 of the artificial poly(A) sequence (e.g., between nucleotides 26 to 39, 27 to 39, 28 to 39, 29 to 39, 30 to 39, 31 to 39, 32 to 39, 33 to 39, 34 to 39, 35 to 39, 36 to 39, or 37 to 39), wherein the last nucleotide in the artificial poly(A) sequence is not a cytosine.

[0047] In particular, the artificial poly(A) sequence may contain about 60 adenines, and between the 41st and 59th nucleotides of the artificial poly(A) sequence, at least one adenine is substituted with cytosine and at least one adenine is substituted with uridine or guanosine (e.g., at least one adenine is substituted with cytosine, at least one adenine is substituted with uridine, and at least one adenine is substituted with guanosine up to page 7 / 16 of the specification, CN 121368634 A), wherein the last nucleotide in the artificial poly(A) sequence is not cytosine. In some embodiments of such an artificial poly(A) sequence, the sequence may contain 1 to 24 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24) cytosines. In some embodiments of such artificial poly(A) sequences, the sequence may contain 36 to 59 (e.g., 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, or 59) adenines. In some embodiments of this artificial poly(A) sequence, all cytosines in the artificial poly(A) sequence are located between nucleotides 37 and 59 of the artificial poly(A) sequence (e.g., between nucleotides 38 and 59, 39 and 59, 40 and 59, 41 and 59, 42 and 59, 43 and 59, 44 and 59, 45 and 59, 46 and 59, 47 and 59, 48 and 59, 49 and 59, 50 and 59, 51 and 59, 51 and 59, 52 and 59, 43 and 59, 44 and 59, 45 and 59, 46 and 59, 47 and 59, 48 and 59, 49 and 59, 50 ... Between nucleotides 52 and 59, nucleotides 53 and 59, nucleotides 54 and 59, nucleotides 55 and 59, nucleotides 56 and 59, or nucleotides 57 and 59. In some embodiments, all cytosines in the artificial poly(A) sequence are sequentially located, i.e., located in a continuous chain of cytosines without any adenine in between.In some embodiments, all cytosines in the artificial poly(A) sequence are sequentially positioned between nucleotides 37 to 59 of the artificial poly(A) sequence (e.g., between nucleotides 38 to 59, 39 to 59, 40 to 59, 41 to 59, 42 to 59, 43 to 59, 44 to 59, 45 to 59, 46 to 59, 47 to 59, 48 to 59, 49 to 59, 50 to 59, 51 to 59, 52 to 59, 53 to 59, 54 to 59, 5 ... Between nucleotides 54 and 59, nucleotides 55 and 59, nucleotides 56 and 59, or nucleotides 57 and 59, wherein the last nucleotide in the artificial poly(A) sequence is not cytosine.

[0048] In particular, the artificial poly(A) sequence may contain about 100 adenines, and between nucleotides 67 and 99 of the artificial poly(A) sequence, at least one adenine is substituted with cytosine and at least one adenine is substituted with uridine or guanosine (e.g., at least one adenine is substituted with cytosine, at least one adenine is substituted with uridine, and at least one adenine is substituted with guanosine), wherein the last nucleotide in the artificial poly(A) sequence is not cytosine. In some embodiments of such artificial poly(A) sequences, the sequence may contain 1 to 40 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40) cytosines. In some embodiments of such artificial poly(A) sequences, the sequence may contain 60 to 99 (e.g., 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99) adenines.In some embodiments of this artificial poly(A) sequence, all cytosines in the artificial poly(A) sequence are located between nucleotides 61 and 99 of the artificial poly(A) sequence (e.g., between nucleotides 62 and 99, 63 and 99, 64 and 99, 65 and 99, 66 and 99, 67 and 99, 68 and 99, 69 and 99, 70 and 99, 71 and 99, 72 and 99, 73 and 99). Between nucleotides 74 and 99, between nucleotides 75 and 99, between nucleotides 76 and 99, between nucleotides 77 and 99, between nucleotides 78 and 99, between nucleotides 79 and 99, between nucleotides 80 and 99. Between nucleotides 81 and 99, 82 and 99, 83 and 99, 84 and 99, 85 and 99, 86 and 99, 87 and 99, 88 and 99, 89 and 99, 90 and 99, 91 and 99, 92 and 99, 93 and 99, 94 and 99, 95 and 99, 96 and 99, or 97 and 99). In some implementations, all cytosines in the artificial poly(A) sequence are located sequentially, i.e., located in a continuous chain of cytosines without any adenine in between.In some embodiments, all cytosines in the artificial poly(A) sequence are sequentially positioned between nucleotides 61 to 99 of the artificial poly(A) sequence (e.g., between nucleotides 62 to 99, 63 to 99, 64 to 99, 65 to 99, 66 to 99, 67 to 99, 68 to 99, 69 to 99, 70 to 99, 71 to 99, 72 to 99, 73 to 99, 74 to 99). Between nucleotides 75 and 99, nucleotides 76 and 99, nucleotides 77 and 99, nucleotides 78 and 99, nucleotides 79 and 99, nucleotides 80 and 99, nucleotides 81 and 99, nucleotides 82 and 99, nucleotides 83 and 99, nucleotides 84 and 99, nucleotides 85 and 99, and so on. Between nucleotides 86 and 99, nucleotides 87 and 99, nucleotides 88 and 99, nucleotides 89 and 99, nucleotides 90 and 99, nucleotides 91 and 99, nucleotides 92 and 99, nucleotides 93 and 99, nucleotides 94 and 99, nucleotides 95 and 99, nucleotides 96 and 99, or nucleotides 97 and 99), wherein the last nucleotide in the artificial poly(A) sequence is not cytosine.

[0049] In other embodiments of such artificial poly(A) sequences, cytosine in the artificial poly(A) sequence may be distributed throughout the entire length of the artificial poly(A) sequence (i.e., adenine may be located between cytosines).In some embodiments, cytosine in the artificial poly(A) sequence may be distributed between nucleotides 25 to 39 of the artificial poly(A) sequence (e.g., between nucleotides 26 to 39, 27 to 39, 28 to 39, 29 to 39, 30 to 39, 31 to 39, 32 to 39, 33 to 39, 34 to 39, 35 to 39, 36 to 39, or 37 to 39), wherein the last nucleotide in the artificial poly(A) sequence is not cytosine.

[0050] In certain embodiments, this disclosure provides an artificial poly(A) sequence comprising any one of the sequences listed in the specification, page 9 / 16, CN 121368634 A, SEQ ID NO: 1-10. In some embodiments, the artificial poly(A) sequence comprises any one of the sequences in SEQ ID NO: 2-8 and 10.

[0051]

[0052] IV. Expression cassettes and vectors

[0053] This disclosure also provides expression cassettes comprising a promoter and the artificial poly(A) sequence described herein. Such expression cassettes, particularly in the form of reproducible vectors (e.g., DNA plasmids or viral vectors), are useful tools for cloning / subcloning and expressing any coding sequence of a protein. Thus, in some cases, the expression cassette may also comprise a polynucleotide sequence encoding a polypeptide (e.g., the polypeptide may be a therapeutic protein or an antigen (e.g., an antigen from a viral pathogen, bacterial pathogen, or fungal pathogen)) between the promoter and the artificial poly(A) sequence, wherein the polynucleotide sequence is operatively linked to the promoter and the artificial poly(A) sequence. In some embodiments, the polypeptide may be a natural antigen derived from the cell or a portion thereof, such as the OVA MHC class I epitope SIINFEKL (SEQ ID NO: 11) or a portion thereof. In some embodiments, the expression cassette may also contain a multiple cloning site between the promoter and the artificial poly(A) sequence. Furthermore, the expression cassette may contain a transcription start codon and a transcription stop codon, both operatively linked to the promoter and the artificial poly(A) sequence. Additional elements, such as transcription activator or enhancer sequences, may be included in the expression cassette and the vector.

[0054] In some embodiments, the promoter may be homologous or heterologous to the polynucleotide between the promoter and the artificial poly(A) sequence. In some embodiments, the promoter may be inducible.In some embodiments, the promoter may be cell-specific or tissue-specific. In some embodiments, the promoter may be a constitutive promoter. In some embodiments, the expression cassette may be specifically expressed in certain cell and / or tissue types within one or more organs. Optionally, the expression cassette may be constitutively expressed (e.g., using a constitutive promoter). Furthermore, the expression cassette may contain a marker gene that confers an selectable phenotype to the transfected cells. For example, the marker may encode antibiotic resistance, such as resistance to kanamycin, G418, bleomycin, or hygromycin.

[0055] This disclosure also provides expression vectors comprising expression cassettes. Expression vectors are used as a means to deliver the expression cassette to a target destination, such as within a cell. Expression vectors may be transfected into cells. Techniques for transfecting multiple cell types are well known and described in the technical and scientific literature. See, for example, Kim and Eberwine, Anal Bioanal Chem. 397(8):3173-8, 2020. This disclosure also provides host cells containing the expression cassette or expression vector described herein. Once transfected into target cells, a polynucleotide encoding a polypeptide (e.g., a therapeutic protein or antigen (e.g., an antigen from a viral, bacterial, or fungal pathogen)) and an artificial poly(A) sequence can be transcribed into an RNA polynucleotide. In some embodiments, the polypeptide may be a natural antigen derived from the cell or a portion thereof, such as the OVA MHC class I epitope SIINFEKL (SEQ ID NO: 11) or a portion thereof.

[0056] V. Other Modifications

[0057] The artificial poly(A) sequence described herein or RNA polynucleotides containing the artificial poly(A) sequence described herein may contain other modifications to improve their stability.

[0058] To address this issue, modifications to mRNA structural elements have been investigated to improve stability and translation efficiency. These modifications include 5' cap modifications, artificial 5' and 3' UTR sequences, and coding regions with optimized codons. Furthermore, chemical modifications of mRNA molecules (including pseudouridine and 5-methylcytosine) have been observed to increase protein translation while reducing immune responses.

[0059] Modified Nucleotides

[0060] The artificial poly(A) sequence described herein or RNA polynucleotides containing the artificial poly(A) sequence described herein may contain one or more modified nucleotides. A modified nucleobase (or base) refers to a nucleobase having at least one variation that is structurally distinguishable from a naturally occurring nucleobase (i.e., adenine, guanine, cytosine, thymine, or uracil). In some embodiments, the modified nucleobase is functionally interchangeable with its naturally occurring counterpart.Both naturally occurring and modified nucleobases can form hydrogen bonds. Modified nucleobases can help improve the stability of polynucleotides, such as increasing their half-life and preventing intracellular degradation and proteolytic cleavage. In some embodiments, the artificial poly(A) sequence described herein or RNA polynucleotides containing the artificial poly(A) sequence described herein may contain at least one modified nucleobase. Examples of modified nucleobases include, but are not limited to, 5-methylcytosine, 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyladenine, 6-methylguanine, 2-propyladenine, 2-propylguanine, 2-thiouracil, 2-thiothymine, 2-thiocytosine, 5-halouracil, 5-halocytosine, 5-propynyluracil, 5-propynylcytosine, 6-azouracil, 6-azocytosine, 6-azothymine, 5-uracil (pseudouracil), 4- Thioururacil, 8-halogenated adenine, 8-aminoadenine, 8-thioadenine, 8-thioalkyladenine, 8-hydroxyadenine, 8-halogenated guanine, 8-aminoguanine, 8-thioguanine, 8-thioalkylguanine, 8-hydroxyguanine, 5-halogenated uracil, 5-bromouracil, 5-trifluoromethyluracil, 5-halogenated cytosine, 5-bromocytosine, 5-trifluoromethylcytosine, 7-methylguanine, 7-methyladenine, 2-fluoroadenine, 2-aminoadenine, 8-azaguanine, 8-azaadenine, 7-deadenine, 7-deadenine, 3-deadenine, and 3-deadenine.

[0061] Modified Sugars

[0062] The artificial poly(A) sequence described herein or RNA polynucleotides containing the artificial poly(A) sequence described herein may contain one or more modified sugars. A modified sugar is a sugar having at least one variation that is structurally distinguishable from naturally occurring sugars (i.e., ribose in RNA). Modification of the modified sugar can help improve the stability of the artificial poly(A) sequence described herein or RNA polynucleotides containing the artificial poly(A) sequence described herein. In some embodiments, the sugar is a pentofuranosyl sugar. The pentofuranosyl sugar ring of the nucleoside can be modified in various ways, including, but not limited to, adding substituents, particularly at the 2' position of the ring; bridging two non-homogeneous ring atoms to form a bicyclic sugar (i.e., a locked sugar); and substituting the epoxide with atoms or groups such as -S-, -N(R)-, or -C(R1)(R2). Examples of modified sugars include, but are not limited to, sugars that substitute for those described on pages 11 / 16 of this specification, specifically 2'-substituted sugars having 2'-F, 2'-OCH2(2'-OMe) or 2'-O(CH2)2-OCH3 (2'-O-methoxyethyl or 2'-MOE) substituents; and bicyclic sugars.Bicyclic sugars are modified furanopentose sugars containing two fused rings. For example, a bicyclic sugar may have a 2' ring carbon of a furanopentose linked to a 4' ring carbon via one or more carbons (i.e., methylene) and / or heteroatoms (i.e., sulfur, oxygen, or nitrogen). The second ring in the sugar restricts the flexibility of the sugar ring, thus confining the oligonucleotide to a conformation that favors base-pairing interactions with its target nucleic acid. An example of a bicyclic sugar is a locked sugar, which is a furanopentose sugar having a 2'-oxygen linked to a 4' ring carbon via a carbon (i.e., methylene) or a heteroatomation (i.e., sulfur, oxygen, or nitrogen). In some embodiments, locked sugars have a 2'-oxygen linked to a 4' ring carbon via a carbon (i.e., methylene). In other words, locked sugars have 4'-(CH2)-O-2' bridges, such as α-L-methyleneoxy (4'-CH2-O-2') and β-D-methyleneoxy (4'-CH2-O-2'). Nucleosides with locked sugars are called locked nucleosides.

[0063] Other examples of bicyclic sugars include, but are not limited to, (6'S)-6'-methyl bicyclic sugars, aminooxy(4'-CH2-O-N(R)-2') bicyclic sugars, and oxyamino(4'-CH2-N(R)-O-2') bicyclic sugars, wherein R is independently H, a protecting group, or a C1-C12 alkyl group. The substituent at the 2' position may also be selected from allyl, amino, azide, thio, O-allyl, O-C1-C10 alkyl, OCF3, O(CH2)2SCH3, O(CH2)2–O–N(Rm)(Rn), and O–CH2–C(=O)–N(Rm)(Rn), wherein each Rm and Rn is independently H or a substituted or unsubstituted C1-C10 alkyl group.

[0064] In some embodiments, the modified sugar is an unlocked sugar. Unlocked sugars refer to acyclic sugars having a 2',3'-seco acyclic structure, wherein the bond between the 2' and 3' carbons in the furanopentose ring is absent.

[0065] Modified internucleotide bonds

[0066] The artificial poly(A) sequence described herein or RNA polynucleotides containing the artificial poly(A) sequence described herein may contain one or more internucleotide bonds. An internucleotide bond is a backbone bond that links nucleosides. An internucleotide bond may be a naturally occurring internucleotide bond (i.e., a phosphate ester bond, also known as a 3'-5' phosphodiester bond, which is present in DNA and RNA) or a modified internucleotide bond. A modified internucleotide bond is an internucleotide bond having at least one variation that is structurally distinguishable from a naturally occurring internucleotide bond. Modified internucleotide bonds can help improve the stability of the artificial poly(A) sequence described herein or RNA polynucleotides containing the artificial poly(A) sequence described herein.

[0067] Examples of modified internucleotide bonds include, but are not limited to, thiophosphate bonds, dithiophosphate bonds, aminophosphate bonds, diaminophosphate bonds, thioaminophosphate bonds, thiodiaminophosphate bonds, aminophosphate morpholino bonds, and thioaminophosphate morpholino bonds, which are known in the art and described, for example, in Bennett and Swayze, Annu Rev Pharmacol Toxicol. 50:259-293, 2010. A thiophosphate bond is a 3'-5' phosphodiester bond having a sulfur atom for non-bridging oxygen in the phosphate backbone of the oligonucleotide. A dithiophosphate bond is a 3'-5' phosphodiester bond having two sulfur atoms for non-bridging oxygen in the phosphate backbone of the oligonucleotide. A thiophosphate bond is a 3'-5' phosphate bond that has a sulfur atom for non-bridging oxygen and an NH group as a 3'-bridging oxygen in the phosphate backbone of the oligonucleotide. In some embodiments, the artificial poly(A) sequence described herein or the RNA polynucleotide containing the artificial poly(A) sequence described herein has at least one (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39) thiophosphate bond. In some embodiments, all nucleotide internucleotide bonds in the artificial poly(A) sequence described herein or in RNA polynucleotides containing the artificial poly(A) sequence described herein are phosphate thioester bonds.

[0068] vi. Method Description 12 / 16 pages 16 CN 121368634 A

[0069] The artificial poly(A) sequence described herein can be used in methods for enhancing protein expression. This disclosure also provides a method for enhancing the expression of intracellular peptides (e.g., the peptide may be a therapeutic protein or an antigen (e.g., an antigen from a viral pathogen, bacterial pathogen, or fungal pathogen)) by transfecting cells with an expression vector containing an expression cassette, wherein the expression cassette contains a promoter operatively linked to a polynucleotide sequence encoding the peptide and the artificial poly(A) sequence described herein, and wherein the artificial poly(A) sequence is linked to the 3' end of the polynucleotide sequence. In some embodiments, the peptide may be a natural antigen or a portion thereof from the cell, such as the OVA MHC class I epitope SIINFEKL (SEQ ID NO:11) or a portion thereof.Once the expression vector is transfected into cells, a polypeptide (e.g., a therapeutic protein or antigen (e.g., an antigen from a viral, bacterial, or fungal pathogen)) can be generated from the expression cassette. RNA polynucleotides containing an artificial poly(A) sequence are more stable and have a longer half-life compared to corresponding RNA polynucleotides without an artificial poly(A) sequence, which subsequently leads to increased protein expression.

[0070] RNA Delivery

[0071] In addition to transfecting cells with an expression vector containing an expression cassette so that RNA polynucleotides containing an artificial poly(A) sequence can be transcribed intracellularly to produce proteins encoded by the expression vector, RNA polynucleotides can also be delivered directly into cells. Examples of RNA delivery systems include, but are not limited to, polymers, exosomes, liposomes, and emulsions. In some embodiments, RNA polynucleotides containing the artificial poly(A) sequence described herein can be loaded or packaged in liposomes or exosomes that specifically target cell types, tissues, or organs. For example, exosomes are small membrane-bound vesicles of endocytosis that are released into the extracellular environment after fusion of a multivesicular body with the plasma membrane. Exosome production from numerous immune cells, including B cells, T cells, and dendritic cells, has been described. Techniques for loading therapeutic compounds (i.e., RNA polynucleotides containing an artificial poly(A) sequence) into exosomes are known in the art and described in, for example, U.S. Patent Publications US 20130053426 and US 20140348904, and International Patent Publication WO 2015002956, which are incorporated herein by reference. In some embodiments, therapeutic compounds can be loaded into exosomes via electroporation or using transfection reagents (i.e., cationic liposomes). In some embodiments, cells that produce exosomes can be engineered to produce exosomes and load them with a therapeutic compound (i.e., RNA polynucleotides containing an artificial poly(A) sequence). For example, exosomes can be loaded by transforming or transfecting host cells that produce exosomes with a genetic construct expressing the therapeutic compound (i.e., RNA polynucleotides containing an artificial poly(A) sequence), such that when the host cells produce exosomes, the therapeutic compound is absorbed into the exosomes.

[0072] Various targeting portions can be introduced into exosomes, thereby allowing the exosomes to be targeted to selected cell types, tissues, or organs. The targeting portion may bind to cell surface receptors or other cell surface proteins or peptides that are specific to the targeted cell type, tissue, or organ. In some embodiments, the exosome has a targeting portion expressed on its surface. In some embodiments, the targeting portion expressed on the exosome surface is fused to an exosome transmembrane protein.Techniques for introducing targeted portions into exosomes are known in the art and are described, for example, in U.S. Patent Publications 20130053426 and 20140348904, and International Patent Publication WO 2015002956, which are incorporated herein by reference.

[0073] Examples

[0074] Example 1 – Method

[0075] Table 1 shows the nucleotide sequences of the poly(A) tails used in all samples. All poly(A) tail sequences were incorporated into the DNA template encoding enhanced green fluorescent protein (EGFP) using PCR (Q5® High Fidelity 2X Premix) (NEB). The purified PCR products were used directly for in vitro mRNA synthesis using the MEGAscript™ T7 Transcription Kit (Invitrogen). To compare EGFP-40A, EGFP-31A8CA, EGFP-30AG8CA, EGFP-30A4CGCA, EGFP-30A8CGA, EGFP-30AU8CA, EGFP-30A4CUCA, and EGFP-30A8CUA, mRNA was synthesized using adenosine triphosphate, cytidine triphosphate, uridine triphosphate, guanosine triphosphate, and an antiretroviral cap analog (“ARCA”; TriLink BioTechnologies) in a molar ratio of 5:5:5:1:4. To compare EGFP-40A, EGFP-31A8CA, EGFP-100A, and EGFP-79A20CA, two sets of mRNAs were synthesized, including (1) the conditions used above, and (2) a molar ratio of 5:5:5:1:4 for adenosine triphosphate, cytidine triphosphate, uridine triphosphate, guanosine triphosphate, and m7G(5')ppp(5')G RNA cap structural analog (G cap) (NEB). All cells were cultured and passaged using standard medium and standard trypsin protocol. Lipofectamine™ MessengerMax™ (Thermofisher) was used for transfection of all mRNAs according to the manufacturer's protocol. For all transfections, 15 ng of iRFP-encoding mRNA was co-transfected for positive cell selection. Cells were collected 24 hours post-transfection and analyzed by flow cytometry using an Attune NxT flow cytometer (Invitrogen).

[0076] Table 1

[0077]

[0078] Example 2 – Non-adenosine can be inserted into the cytidine-containing tail while preserving the protein enhancement effect

[0079] Uric acid and guanosine are inserted into the cytidine-containing tail (before the cytidine sequence, between the cytidine sequences, and after the cytidine sequence; as shown in Table 1).HEK293 cells were seeded in 48-well plates 24 hours before transfection at a rate of 0.5 × 10⁵ cells / well. HEK293 cells were transfected with mRNA encoding EGFP with different tails. A total of 15 ng of mRNA encoding iRFP was transfected into all samples for positive cell selection. Cell suspensions were collected 24 hours post-transfection using a standard trypsin protocol. EGFP and iRFP protein expression were determined by flow cytometry using an Attune NxT flow cytometer (Invitrogen). EGFP intensity was recorded in iRFP-positive cells. Readings were compared to those of EGFP-40A. As shown in Figure 1, we observed enhanced protein expression in all EGFPs with cytidine-containing tails (regardless of non-adenosine insertion) compared to EGFP-40A.

[0080] Example 3—Cytidine-containing tails can induce higher protein translation expression of natively capped mRNA compared to ARCA-capped mRNA

[0081] Existing mRNA therapies and vaccines employ antiretroviral cap analogs (ARCA) [1]. Two groups of EGFP-40A and EGFP-31A8CA were synthesized (Group 1 carries a native mRNA cap (G cap); Group 2 carries an ARCA cap). HEK293 cells were seeded in 48-well plates 24 hours before transfection at 0.5 × 10⁵ cells / well. HEK293 cells were transfected with EGFP-40A and EGFP-31A8CA carrying either a G cap or an ARCA cap. 15 ng of iRFP-encoding mRNA was transfected into all samples for positive transfection cell selection. Cell suspensions were collected 24 hours after transfection using a standard trypsin protocol. EGFP and iRFP protein expression were determined by flow cytometry using an Attune NxT flow cytometer (Invitrogen). The EGFP intensity of iRFP-positive cells was recorded. The readings were compared with those of EGFP-40A. As shown in Figure 2, both groups transfected with EGFP-31A8CA showed increased protein yield compared to the group transfected with EGFP-40A. Importantly, EGFP-31A8CA with a natural cap showed nearly 2.5-fold protein expression compared to EGFP-40A with an ARCA cap.

[0082] Example 4—Cytidine-containing tails can induce higher protein translation expression of naturally capped mRNAs than that of ARCA-capped mRNAs, regardless of cell type.

[0083] Furthermore, the same experiment was repeated on MCF-7 cells. MCF-7 cells were seeded in 48-well plates 24 hours before transfection at 0.5 × 10⁵ cells / well.MCF-7 cells were transfected with EGFP-40A and EGFP-31A8CA carrying G-caps or ARCA caps. A total of 15 ng of iRFP-encoding mRNA was transfected into all samples for positive cell selection. Cell suspensions were collected 24 hours post-transfection using a standard trypsin protocol. EGFP and iRFP protein expression was determined by flow cytometry using an Attune NxT flow cytometer (Invitrogen). EGFP intensity in iRFP-positive cells was recorded. As shown in Figure 3, similar results to those observed in HEK293 cells were observed, indicating that the enhancement effect was independent of cell type.

[0084] Example 5 – Comparison of various tails with 100 nucleotides

[0085] Synthesized mRNAs typically have a poly(A) tail length of approximately 100 nucleotides [2-4]. We compared the protein yield of EGFP-encoding mRNAs with native and ARCA caps and tail lengths of 100 nt (carrying 100A or 79A20CA). HEK293 cells were seeded in 48-well plates 24 hours before transfection at a rate of 0.5 × 10⁵ cells / well. HEK293 cells were transfected with EGFP-100A and EGFP-79A20CA, which were either G-capped or ARCA-capped. A total of 15 ng of iRFP-encoding mRNA was transfected into all samples for positive cell selection. Cell suspensions were collected 24 hours post-transfection using a standard trypsin protocol. EGFP and iRFP protein expression was measured by flow cytometry using an Attune NxT flow cytometer (Invitrogen). EGFP intensity was recorded for iRFP-positive cells. Readings were compared to those for EGFP-40A. As shown in Figure 4, EGFP-79A20CA with a natural cap achieved approximately 1.5-fold higher EGFP expression compared to ARCA-capped EGFP with a pure adenosine tail.References

[0087] [1] STEPINSKI, JANUSZ, et al. "Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl (3'-O-methyl) GpppG and 7-methyl (3'-deoxy) GpppG," RNA 7.10, 1486-1495, 2001 [2] Gebre, M.S., Rauch, S., Roth, N. et al., "Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine," Nature 601, 410-414, 2022

[0089] [3] Vogel, A.B., Kanevsky, I., Che, Y . et al ., “BNT162b vaccines protect "rhesus macaques from SARS-CoV-2," Nature 592, 283-289, 2021

[0090] [4] Krawczyk, PS, Gewartowska, O., Mazur, M., et al., "SARS-CoV-2 mrna vaccine is re-adenlyated in vivo, enhancing antigen production and immune response," 2022 https: / / www.biorxiv.org / content / 10.1101 / 2022.12.01.58149v2

[0091] The above embodiments are provided to illustrate the present disclosure but do not limit its scope. Other variations of the present disclosure will be apparent to those skilled in the art from pages 15 / 16 of the specification, 19 CN 121368634 A, and are covered by the appended claims. All publications, databases, Internet resources, patents, patent applications and accession numbers cited herein are incorporated herein by reference in their entirety for all purposes.Instruction manual 16 / 16 pages 20 CN 121368634 A Figure 1 Instruction manual figure 1 / 4 pages 21 CN 121368634 A Figure 2 Instruction manual figure 2 / 4 pages 22 CN 121368634 A Figure 3 Instruction manual figure 3 / 4 pages 23 CN 121368634 A Figure 4 Instruction manual figure 4 / 4 pages 24 CN 121368634 A.

Claims

1. An artificial poly(A) sequence comprising about 30-150 adenines, wherein in the last third of the artificial poly(A) sequence closest to its 3’ end, at least one adenine is substituted with a cytosine and at least one adenine is substituted with a uridine or guanosine.

2. The artificial poly(A) sequence of claim 1, wherein in the last third of the artificial poly(A) sequence closest to its 3’ end, at least one adenine is substituted with a cytosine, at least one adenine is substituted with a uridine, and at least one adenine is substituted with a guanosine.

3. The artificial poly(A) sequence of claim 1 or 2, wherein the artificial poly(A) sequence comprises 18 to 129 adenines.

4. The artificial poly(A) sequence of any one of claims 1 to 3, wherein the last nucleotide in the artificial poly(A) sequence is not a cytosine.

5. The artificial poly(A) sequence of any one of claims 1 to 4, wherein up to 40% of the nucleotides in the artificial poly(A) sequence are cytosines.

6. The artificial poly(A) sequence of claim 5, wherein up to 25% of the nucleotides in the artificial poly(A) sequence are cytosines.

7. The artificial poly(A) sequence of any one of claims 1 to 6, wherein the majority of the cytosines in the artificial poly(A) sequence are located in the last third of the artificial poly(A) sequence closest to its 3’ end.

8. The artificial poly(A) sequence of any one of claims 1 to 7, wherein all of the cytosines in the artificial poly(A) sequence are located contiguously.

9. The artificial poly(A) sequence of any one of claims 1 to 8, wherein the artificial poly(A) sequence comprises about 40 adenines, and between the 27th and 39th nucleotide of the artificial poly(A) sequence, at least one adenine is substituted with a cytosine and at least one adenine is substituted with a uridine or guanosine.

10. The artificial poly(A) sequence of any one of claims 1 to 9, wherein the artificial poly(A) sequence comprises about 40 adenines, and between the 27th and 39th nucleotide of the artificial poly(A) sequence, at least one adenine is substituted with a cytosine, at least one adenine is substituted with a uridine, and at least one adenine is substituted with a guanosine.

11. The artificial poly(A) sequence of claim 9 or 10, wherein the artificial poly(A) sequence comprises 24 to 39 adenines.

12. The artificial poly(A) sequence of any one of claims 9 to 11, wherein the artificial poly(A) sequence comprises 1 to 16 cytosines.

13. The artificial poly(A) sequence of any one of claims 9 to 12, wherein all cytosines in the artificial poly(A) sequence are located between the 25th nucleotide and the 39th nucleotide of the artificial poly(A) sequence.

14. The artificial poly(A) sequence of any one of claims 9 to 13, wherein all cytosines in the artificial poly(A) sequence are located consecutively.

15. The artificial poly(A) sequence of any one of claims 9 to 14, wherein the last nucleotide in the artificial poly(A) sequence is not a cytosine.

16. The artificial poly(A) sequence of any one of claims 1 to 8, wherein the artificial poly(A) sequence comprises about 60 adenines, and between the 41st nucleotide and the 59th nucleotide of the artificial poly(A) sequence, at least one adenine is replaced with a cytosine and at least one adenine is replaced with a uridine or guanosine.

17. The artificial poly(A) sequence of claim 16, wherein the artificial poly(A) sequence comprises 36 to 59 adenines.

18. The artificial poly(A) sequence of claim 16 or 17, wherein the artificial poly(A) sequence comprises 1 to 24 cytosines.

19. The artificial poly(A) sequence of any one of claims 16 to 18, wherein all cytosines in the artificial poly(A) sequence are located between the 37th nucleotide and the 59th nucleotide of the artificial poly(A) sequence.

20. The artificial poly(A) sequence of any one of claims 16 to 19, wherein all cytosines in the artificial poly(A) sequence are located consecutively.

21. The artificial poly(A) sequence of any one of claims 16 to 20, wherein the last nucleotide in the artificial poly(A) sequence is not a cytosine.

22. The artificial poly(A) sequence of any one of claims 1 to 8, wherein the artificial poly(A) sequence comprises about 100 adenines, and between the 67th nucleotide and the 99th nucleotide of the artificial poly(A) sequence, at least one adenine is replaced with a cytosine and at least one adenine is replaced with a uridine or guanosine.

23. The artificial poly(A) sequence of claim 22, wherein the artificial poly(A) sequence comprises 60 to 99 adenines.

24. The artificial poly(A) sequence of claim 22 or 23, wherein the artificial poly(A) sequence comprises 1 to 40 cytosines.

25. The artificial poly(A) sequence of any one of claims 22 to 24, wherein all cytosines in the artificial poly(A) sequence are located between the 61st nucleotide and the 99th nucleotide of the artificial poly(A) sequence.

26. The artificial poly(A) sequence of any one of claims 22-25, wherein all cytosines in the artificial poly(A) sequence are positioned consecutively.

27. The artificial poly(A) sequence of any one of claims 22-26, wherein the last nucleotide in the artificial poly(A) sequence is not a cytosine.

28. The artificial poly(A) sequence of any one of claims 1-27, wherein the artificial poly(A) sequence comprises the sequence of any one of SEQ ID NOs: 2-8 and 10.

29. An expression cassette comprising a promoter and a polynucleotide sequence encoding the artificial poly(A) sequence of any one of claims 1-27.

30. The expression cassette of claim 29, further comprising a multiple cloning site between the promoter and the polynucleotide sequence encoding the artificial poly(A) sequence.

31. The expression cassette of claim 29 or 30, further comprising a transcriptional start codon and a transcriptional stop codon, both operably linked to the promoter and the polynucleotide sequence encoding the artificial poly(A) sequence.

32. The expression cassette of any one of claims 29-31, further comprising a polynucleotide sequence encoding a polypeptide between the promoter and the artificial poly(A) sequence, wherein the polynucleotide sequence is operably linked to the promoter and the polynucleotide sequence encoding the artificial poly(A) sequence.

33. An expression vector comprising the expression cassette of any one of claims 29-32.

34. A host cell comprising the expression cassette of any one of claims 29-32 or the expression vector of claim 33.

35. An RNA polynucleotide expressed from the expression cassette of claim 32.

36. An RNA molecule comprising a coding sequence for a polypeptide and the artificial poly(A) sequence of any one of claims 1-27.

37. A method of increasing protein expression of a polypeptide in a cell, comprising transfecting the cell with the expression vector of claim 33.